The rising prevalence of small lymphocytic lymphoma is responsible for the upsurge in research and development of therapeutics that can control progression of the disease, and in turn lead to discovery of new targets that would assist in curing cancer. Increasing adoption of unhealthy lifestyle, unchecked use of pesticides in cultivating crops and fruits along with intake of unhygienic food items causes virus infection such as Hepatitis C and Epstein-Barr virus, which may trigger the incidence of small lymphocytic lymphoma. Therefore, the therapeutic pipeline of small lymphocytic lymphoma is increasing in consequent manner. Consequently, increase in healthcare awareness among consumers is further supplementing growth of small lymphocytic lymphoma therapeutics pipeline.
Small lymphocytic lymphoma is a sort of non-Hodgkin lymphoma, which generally affects the B-lymphocytes of the immune system that are present in the lymphoid tissue such as tonsils and spleen, and lymph nodes. However, small lymphocytic lymphoma has many similarities with chronic lymphocytic leukaemia, which acts on the B-lymphocytes that are present in the bone marrow and blood. The observed symptoms of small lymphocytic lymphoma are loss of appetite, night sweats, fever, fatigue, weight loss, etc.
In October 2016, Janssen Research & Development, LLC started a Phase II study of the combination of Ibrutinib, which is bruton’s tyrosine kinase (BTK) inhibitor; and Venetoclax, which is a BCL-2 inhibitor and an antiapoptotic protein, in subjects undergoing the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. This study is expected to be completed by September 2021. In December 2013, Verastem Inc., started a Phase III extension study of Duvelisib and Ofatumumab in patients suffering from chronic lymphocytic leukemia/ small lymphocytic lymphoma, previously enrolled in the study IPI-145-07. This study is expected to be completed by December 2018. In January 2017, Genentech Inc., started a Phase II study of combination of drugs – Atezolizumab, with Obinutuzumab and Ibrutinib, for the treatment of small lymphocytic lymphoma. This study is expected to be completed by January 2021.
Request for table of Content at: https://www.psmarketresearch.com/market-analysis/small-lymphocytic-lymphoma-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of small lymphocytic lymphoma therapeutics include Janssen Research & Development, LLC, Boehringer Ingelheim GmbH, Verastem, Inc., Celgene Corporation, Shanghai Zhangjiang Biotechnology Limited Company, TG Therapeutics, Inc.